Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9Y2B2

UPID:
PIGL_HUMAN

ALTERNATIVE NAMES:
Phosphatidylinositol-glycan biosynthesis class L protein

ALTERNATIVE UPACC:
Q9Y2B2; A8KA67; B4DYN4

BACKGROUND:
N-acetylglucosaminyl-phosphatidylinositol de-N-acetylase, alternatively known as Phosphatidylinositol-glycan biosynthesis class L protein, is pivotal in GPI biosynthesis' de-N-acetylation step. This enzymatic activity is critical for cell surface protein anchoring.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of N-acetylglucosaminyl-phosphatidylinositol de-N-acetylase offers a promising avenue for developing treatments for a rare multisystem disorder characterized by colobomas, heart defects, and more, caused by gene variants affecting this protein.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.